Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, advanced melanoma. These efficient therapies are well tolerated with mostly moderate and...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzerling, Lucie, Eigentler, Thomas K, Fluck, Michael, Hassel, Jessica C, Heller-Schenck, Daniela, Leipe, Jan, Pauschinger, Matthias, Vogel, Arndt, Zimmer, Lisa, Gutzmer, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555610/
https://www.ncbi.nlm.nih.gov/pubmed/31231568
http://dx.doi.org/10.1136/esmoopen-2019-000491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555610/
https://www.ncbi.nlm.nih.gov/pubmed/31231568
http://dx.doi.org/10.1136/esmoopen-2019-000491

Ejemplares similares